Anaerobes: Antibiotic resistance, clinical significance, and the role of susceptibility testing

National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 6th ed. M11-A6, 2004.

Goldstein, 1995, United States national hospital survey of anaerobic culture and susceptibility methods, Anaerobe, 1, 309, 10.1006/anae.1995.1032

Snydman, 2002, National survey on the susceptibility of Bacteroides fragilis Group: report and analysis of trends for 1997–2000, Clin Infect Dis, 35, S126, 10.1086/341934

Hecht, 1993, Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals, Clin Infect Dis, 16, S357, 10.1093/clinids/16.Supplement_4.S357

Snydman, 1999, Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995–1996, with comparison of resistance trends from 1990 to 1996, Antimicrob Agents Chemother, 43, 2417, 10.1128/AAC.43.10.2417

Aldridge, 2001, Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species, Antimicrob Agents Chemother, 45, 1238, 10.1128/AAC.45.4.1238-1243.2001

Koeth, 2004, Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents, J Antimicrob Chemother, 53, 1039, 10.1093/jac/dkh248

Bianchini, 1997, Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20-year study at a medical center in Buenos Aires, Argentina, Clin Infect Dis, 25, S268, 10.1086/516192

Labbe, 1999, Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada, Antimicrob Agents Chemother, 43, 2517, 10.1128/AAC.43.10.2517

Lubbe, 1999, Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa, Eur J Clin Microbiol Infect Dis, 18, 46, 10.1007/s100960050225

Shore, 1999, Susceptibility of anaerobic bacteria in Auckland: 1991–1996, N Z Med J, 112, 424

Hecht, 2004, Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments, Clin Infect Dis, 39, 92, 10.1086/421558

Hecht, 1995, Effect of choice of medium on the results of in vitro susceptibility testing of eight antibiotics against the Bacteroides fragilis group, Clin Infect Dis, 20, S346, 10.1093/clinids/20.Supplement_2.S346

Appelbaum, 1990, Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance, Antimicrob Agents Chemother, 34, 2169, 10.1128/AAC.34.11.2169

Giraud-Morin, 2003, Sequence analysis of cfxA2-like beta-lactamases in Prevotella species, J Antimicrob Chemother, 51, 1293, 10.1093/jac/dkg221

Bennion, 1990, Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology, Clin Ther, 12, 31

Rogers, 1993, Cloning and characterization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of Ambler class A beta-lactamases, Antimicrob Agents Chemother, 37, 2391, 10.1128/AAC.37.11.2391

Thompson, 1990, Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis TAL2480 reveals strong similarity between CfiA and Bacillus cereus beta-lactamase II, J Bacteriol, 172, 2584, 10.1128/jb.172.5.2584-2593.1990

Rasmussen, 1990, Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636, Antimicrob Agents Chemother, 34, 1590, 10.1128/AAC.34.8.1590

Podglajen, 1995, Genotypic identification of two groups within the species Bacteroides fragilis by ribotyping and by analysis of PCR-generated fragment patterns and insertion sequence content, J Bacteriol, 177, 5270, 10.1128/jb.177.18.5270-5275.1995

Podglajen, 1994, Insertion of a novel DNA sequence, 1S1186, upstream of the silent carbapenemase gene cfiA, promotes expression of carbapenem resistance in clinical isolates of Bacteroides fragilis, Mol Microbiol, 12, 105, 10.1111/j.1365-2958.1994.tb00999.x

Soki, 2004, Molecular characterization of imipenem-resistant, cfiA-positive Bacteroides fragilis isolates from the USA, Hungary and Kuwait, J Med Microbiol, 53, 413, 10.1099/jmm.0.05452-0

Kato, 2003, New insertion sequence elements in the upstream region of cfiA in imipenem-resistant Bacteroides fragilis strains, Antimicrob Agents Chemother, 47, 979, 10.1128/AAC.47.3.979-985.2003

Wexler, 1990, Alterations to the penicillin-binding proteins in the Bacteroides fragilis group: a mechanism for non-beta-lactamase mediated cefoxitin resistance, J Antimicrob Chemother, 26, 7, 10.1093/jac/26.1.7

Fang, 2002, Selection of cefoxitin-resistant bacteroides thetaiotaomicron mutants and mechanisms involved in beta-lactam resistance, Clin Infect Dis, 35, S47, 10.1086/341920

Wexler, 2002, Outer-membrane pore-forming proteins in Gram-negative anaerobic bacteria, Clin Infect Dis, 35, S65, 10.1086/341923

Hedberg, 2003, Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe, Clin Microbiol Infect, 9, 475, 10.1046/j.1469-0691.2003.00674.x

Rasmussen, 1997, Antimicrobial resistance in anaerobes, Clin Infect Dis, 24, S110, 10.1093/clinids/24.Supplement_1.S110

Cooper, 1996, The erythromycin resistance gene from the Bacteroides conjugal transposon Tcr Emr 7853 is nearly identical to ermG from Bacillus sphaericus, Antimicrob Agents Chemother, 40, 506, 10.1128/AAC.40.2.506

Gupta, 2003, A new Bacteroides conjugative transposon that carries an ermB gene, Appl Environ Microbiol, 69, 6455, 10.1128/AEM.69.11.6455-6463.2003

Tally, 1979, Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis, J Infect Dis, 139, 83, 10.1093/infdis/139.1.83

Whittle, 2002, The role of Bacteroides conjugative transposons in the dissemination of antibiotic resistance genes, Cell Mol Life Sci, 59, 2044, 10.1007/s000180200004

Shoemaker, 2001, Evidence for extensive resistance gene transfer among Bacteroides spp. and among Bacteroides and other genera in the human colon, Appl Environ Microbiol, 67, 561, 10.1128/AEM.67.2.561-568.2001

Schapiro, 2004, Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State, J Clin Microbiol, 42, 4127, 10.1128/JCM.42.9.4127-4129.2004

Lamothe, 1986, Bacteroides fragilis resistant to both metronidazole and imipenem, J Antimicrob Chemother, 18, 642, 10.1093/jac/18.5.642

Rotimi, 1999, Bacteroides species highly resistant to metronidazole: an emerging clinical problem?, Clin Microbiol Infect, 5, 166, 10.1111/j.1469-0691.1999.tb00531.x

Haggoud, 1994, Nucleotide sequence analysis of two 5-nitroimidazole resistance determinants from Bacteroides strains and of a new insertion sequence upstream of the two genes, Antimicrob Agents Chemother, 38, 1047, 10.1128/AAC.38.5.1047

Carlier, 1997, Metabolism of a 5-nitroimidazole in susceptible and resistant isogenic strains of Bacteroides fragilis, Antimicrob Agents Chemother, 41, 1495, 10.1128/AAC.41.7.1495

Trinh, 1995, Plasmids pIP419 and pIP421 from Bacteroides: 5-nitroimidazole resistance genes and their upstream insertion sequence elements, Microbiology, 141, 927, 10.1099/13500872-141-4-927

Lofmark, 2005, Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates, Antimicrob Agents Chemother, 49, 1253, 10.1128/AAC.49.3.1253-1256.2005

Diniz, 2004, Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant, J Antimicrob Chemother, 54, 100, 10.1093/jac/dkh256

Golan, 2003, Emergence of fluoroquinolone resistance among Bacteroides species, J Antimicrob Chemother, 52, 208, 10.1093/jac/dkg320

Oh, 2002, Efflux-mediated fluoroquinolone resistance in the Bacteroides fragilis group, Anaerobe, 8, 277, 10.1006/anae.2003.0439

Ricci, 2003, Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones, J Antimicrob Chemother, 52, 605, 10.1093/jac/dkg418

Oh, 2004, Mechanism of quinolone resistance in anaerobic bacteria, Clin Microbiol Infect, 9, 512, 10.1046/j.1469-0691.2003.00725.x

Ricci, 2004, Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants, Antimicrob Agents Chemother, 48, 1344, 10.1128/AAC.48.4.1344-1346.2004

Livermore, 2005, Tigecycline: what is it, and where should it be used?, J Antimicrob Chemother, 56, 611, 10.1093/jac/dki291

Hecht, 1999, Anaerobe resistance among anaerobes: what now?, Anaerobe, 5, 421, 10.1006/anae.1999.0227

Hecht, 2003, Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates, Antimicrob Agents Chemother, 47, 910, 10.1128/AAC.47.3.910-916.2003

Matto, 1999, Beta-lactamase production in Prevotella intermedia, Prevotella nigrescens, and Prevotella pallens genotypes and in vitro susceptibilities to selected antimicrobial agents, Antimicrob Agents Chemother, 43, 2383, 10.1128/AAC.43.10.2383

Handal, 2005, Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis, FEMS Microbiol Lett, 242, 319, 10.1016/j.femsle.2004.11.023

Roberts, 2003, Acquired tetracycline and/or macrolide-lincosamides-stretogramin resistance in anaerobes, Anaerobe, 9, 63, 10.1016/S1075-9964(03)00058-1

King, 1999, Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe, Clin Microbiol Infect, 5, 404, 10.1111/j.1469-0691.1999.tb00164.x

Scott, 2000, Occurrence of the new tetracycline resistance gene tet(W) in bacteria from the human gut, Antimicrob Agents Chemother, 44, 775, 10.1128/AAC.44.3.775-777.2000

Arzese, 2000, Detection of tetQ and ermF antibiotic resistance genes in Prevotella and Porphyromonas isolates from clinical specimens and resident microbiota of humans, J Antimicrob Chemother, 45, 577, 10.1093/jac/45.5.577

Roberts, 2005, Update on acquired tetracycline resistance genes, FEMS Microbiol Lett, 245, 195, 10.1016/j.femsle.2005.02.034

Nikolich, 1994, Evidence for natural horizontal transfer of tetQ between bacteria that normally colonize humans and bacteria that normally colonize livestock, Appl Environ Microbiol, 60, 3255, 10.1128/AEM.60.9.3255-3260.1994

Johnson, 1993, Susceptibility of anaerobic bacteria to beta-lactam antibiotics in the United States, Clin Infect Dis, 16, S371, 10.1093/clinids/16.Supplement_4.S371

Nyfors, 2003, Emergence of penicillin resistance among Fusobacterium nucleatum populations of commensal oral flora during early childhood, J Antimicrob Chemother, 51, 107, 10.1093/jac/dkg022

McKay, 1995, Mobile genetic elements of Fusobacterium nucleatum, Plasmid, 33, 15, 10.1006/plas.1995.1003

Baron, 1993, Bactericidal activity of selected antimicrobial agents against Bilophila wadsworthia and Bacteroides gracilis, Clin Infect Dis, 16, S339, 10.1093/clinids/16.Supplement_4.S339

Finegold, 1992, Clinical importance of Bilophila wadsworthia, Eur J Clin Microbiol Infect Dis, 11, 1058, 10.1007/BF01967799

Molitoris, 1997, Sources and antimicrobial susceptibilities of Campylobacter gracilis and Sutterella wadsworthensis, Clin Infect Dis, 25, S264, 10.1086/516234

Wexler, 2002, In vitro activities of faropenem against 579 strains of anaerobic bacteria, Antimicrob Agents Chemother, 46, 3669, 10.1128/AAC.46.11.3669-3675.2002

Goldstein, 1999, Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes, Antimicrob Agents Chemother, 43, 2726, 10.1128/AAC.43.11.2726

Pelak, 2002, Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection, J Antimicrob Chemother, 50, 735, 10.1093/jac/dkf203

Hecht, 1996, In vitro susceptibility of anaerobes to quinolones in the United States, Clin Infect Dis, 23, S2, 10.1093/clinids/23.Supplement_1.S2

Goldstein, 1999, In vitro activity of gemifloxacin (SB 265805) against anaerobes, Antimicrob Agents Chemother, 43, 2231, 10.1128/AAC.43.9.2231

Goldstein, 1999, Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes, Antimicrob Agents Chemother, 43, 2726, 10.1128/AAC.43.11.2726

Jamal, 2002, In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait, Int J Antimicrob Agents, 20, 270, 10.1016/S0924-8579(02)00180-2

Ackermann, 2003, Prevalence and association of macrolide–lincosamide–streptogramin B (MLS(B)) resistance with resistance to moxifloxacin in Clostridium difficile, J Antimicrob Chemother, 51, 599, 10.1093/jac/dkg112

Farrow, 2001, Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile, Microbiology, 147, 2717, 10.1099/00221287-147-10-2717

Farrow, 2002, Identification of essential residues in the Erm(B) rRNA methyltransferase of Clostridium perfringens, Antimicrob Agents Chemother, 46, 1253, 10.1128/AAC.46.5.1253-1261.2002

Johansson, 2004, Antimicrobial susceptibility of Swedish, Norwegian and Danish isolates of Clostridium perfringens from poultry, and distribution of tetracycline resistance genes, Vet Microbiol, 99, 251, 10.1016/j.vetmic.2004.01.009

Sloan, 1994, The Clostridium perfringens Tet P determinant comprises two overlapping genes: tetA(P), which mediates active tetracycline efflux, and tetB(P), which is related to the ribosomal protection family of tetracycline-resistance determinants, Mol Microbiol, 11, 403, 10.1111/j.1365-2958.1994.tb00320.x

Finegold, 2005, Clostridium clostridioforme: a mixture of three clinically important species, Eur J Clin Microbiol Infect Dis, 24, 319, 10.1007/s10096-005-1334-6

Bendle, 2004, Resistance determinants in strains of Clostridium difficile from two geographically distinct populations, Int J Antimicrob Agents, 24, 619, 10.1016/j.ijantimicag.2004.06.013

Adams, 2002, The clostridial mobilisable transposons, Cell Mol Life Sci, 59, 2033, 10.1007/s000180200003

Changela, 2004, Risk factors and mortality associated with Clostridium difficile-associated diarrhoea at a VA hospital, Int J Antimicrob Agents, 24, 562, 10.1016/j.ijantimicag.2004.07.011

Dridi, 2002, gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile, Antimicrob Agents Chemother, 46, 3418, 10.1128/AAC.46.11.3418-3421.2002

Rafii, 2005, Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones, Antimicrob Agents Chemother, 49, 488, 10.1128/AAC.49.2.488-492.2005

Song, 2003, 16S ribosomal DNA sequence-based analysis of clinically significant Gram-positive anaerobic cocci, J Clin Microbiol, 41, 1363, 10.1128/JCM.41.4.1363-1369.2003

Hoellman, 2001, Comparative antianaerobic activity of BMS 284756, Antimicrob Agents Chemother, 45, 589, 10.1128/AAC.45.2.589-592.2001

Brazier, 2003, Antibiotic susceptibilities of Gram-positive anaerobic cocci: results of a sentinel study in England and Wales, J Antimicrob Chemother, 52, 224, 10.1093/jac/dkg316

Baquero, 1992, Resistance of anaerobic bacteria to antimicrobial agents in Spain, Eur J Clin Microbiol Infect Dis, 11, 1016, 10.1007/BF01967792

Handal, 2005, Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis, FEMS Microbiol Lett, 242, 319, 10.1016/j.femsle.2004.11.023

Theron, 2004, Nitroimidazole resistance genes (nimB) in anaerobic Gram-positive cocci (previously Peptostreptococcus spp.), J Antimicrob Chemother, 54, 240, 10.1093/jac/dkh270

Hecht, 2002, Evolution of anaerobe susceptibility testing in the United States, Clin Infect Dis, 35, S28, 10.1086/341917

Rosenblatt, 1995, Evaluation of the Etest for susceptibility testing of anaerobic bacteria, Diagn Microbiol Infect Dis, 22, 279, 10.1016/0732-8893(95)00049-G

Bieluch, 1987, Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates, Diagn Microbiol Infect Dis, 7, 119, 10.1016/0732-8893(87)90029-0

Snydman, 1992, Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis, Antimicrob Agents Chemother, 36, 540, 10.1128/AAC.36.3.540

Dalmau, 1997, Clindamycin resistance in the Bacteroides fragilis group: association with hospital-acquired infections, Clin Infect Dis, 24, 874, 10.1093/clinids/24.5.874

Nguyen, 2000, Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial, Clin Infect Dis, 30, 870, 10.1086/313805

Solomkin, 2003, Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections, Clin Infect Dis, 37, 997, 10.1086/378702

Bascones, 2004, Consensus statement on antimicrobial treatment of odontogenic bacterial infections, Med Oral Patol Oral Cir Bucal, 9, 369